Enveric Biosciences, Inc.
ENVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000890821
No open-market purchases or sales by Enveric Biosciences, Inc. insiders were filed in the last 90 days; 24 institutions reported holding it in 13F filings for Q2 2026, worth $736.8K in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Enveric Biosciences, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- −4 vs. Q4 2024
- Shares held
- 253.2K
- −825.9K (−76.5%) vs. Q4 2024
- Total value
- $344.7K
- −$42.0K (−10.9%) vs. Q4 2024
- New holders
- 4
- 2 more added
- Sold out
- 8
- 9 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENVB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 24 | $736.8K |
| Q1 2026 | 11 | $106.6K |
| Q4 2025 | 11 | $87.7K |
| Q3 2025 | 11 | $232.6K |
| Q2 2025 | 14 | $283.2K |
| Q1 2025 | 15 | $344.7K |
| Q4 2024 | 19 | $386.7K |
| Q3 2024 | 17 | $337.2K |
| Q2 2024 | 17 | $307.3K |
| Q1 2024 | 18 | $488.4K |
| Q4 2023 | 15 | $635.8K |
| Q3 2023 | 15 | $518.3K |
| Q2 2023 | 14 | $631.1K |
| Q1 2023 | 13 | $382.4K |
| Q4 2022 | 12 | $356.8K |
| Q3 2022 | 12 | $623.0K |
| Q2 2022 | 27 | $1.99M |
| Q1 2022 | 31 | $3.61M |
| Q4 2021 | 31 | $4.45M |
| Q3 2021 | 24 | $4.64M |
| Q2 2021 | 18 | $2.72M |
| Q1 2021 | 14 | $3.42M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Enveric Biosciences, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AdvisorShares Investments LLC | 90,324 | $118.3K | 0.02% | −509,530−84.9% | Reduced |
| UBS Group AG | 42,760 | $59.4K | 0.00% | −35,648−45.5% | Reduced |
| HRT Financial LP | 40,625 | $56.0K | 0.00% | +40,625 | New |
| Geode Capital Management, LLC | 26,558 | $36.9K | 0.00% | −190,036−87.7% | Reduced |
| Virtu Financial LLC | 25,622 | $36.0K | 0.00% | −30,141−54.1% | Reduced |
| Citadel Advisors LLC | 20,060 | $27.9K | 0.00% | +5,043+33.6% | Added |
| FMR LLC | 3,426 | $4.76K | 0.00% | +3,426 | New |
| Tower Research Capital LLC (TRC) | 2,372 | $3.30K | 0.00% | −6,438−73.1% | Reduced |
| SBI Securities Co., Ltd. | 725 | $1.01K | 0.00% | +706+3,715.8% | Added |
| BlackRock, Inc. | 601 | $835 | 0.00% | −8,409−93.3% | Reduced |
| Headlands Technologies LLC | 110 | $153 | 0.00% | +110 | New |
| Barclays PLC | 30 | $42 | 0.00% | +30 | New |
| Group One Trading, L.P. | 19 | $26 | 0.00% | −254−93.0% | Reduced |
| National Bank of Canada | 5 | $7 | 0.00% | −65−92.9% | Reduced |
| Wells Fargo & Company | 2 | $3 | 0.00% | −14−87.5% | Reduced |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −31,872−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −22,007−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −18,198−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −12,145−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −10,815−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −180−100.0% | Sold out |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Hantz Financial Services, Inc. | 0 | $0 | 0.00% | −1−100.0% | Sold out |